Document is current
Any future updates will be listed below
-
Authors
Allard, Benoit
Ousova, Olga
Savitskaya, Zhanna
Levardon, Hannah
Maurat, Elise
Campagnac, Marilyne
Trian, Thomas
Berger, Patrick
-
Funding
Funding for this research was provided by:
Fondation Bordeaux Université
- License Information
-
More Information
Article History
Received: 6 May 2024
Accepted: 8 August 2024
First Online: 19 August 2024
Declarations
:
: All mice were treated in accordance with the guidelines of the Federation of European Laboratory Animal Science Associations, and protocols were approved by the local animal care committee (N°02712.02).
: Not applicable.
: BA, OO, ZS, HL, EM, MC and TT declare no conflict of interest. PB is the medical coordinator of the French national cohort (i.e., COBRA), which received grants from AstraZeneca, GlaxoSmithKine, Sanofi, and Chiesi. Moreover, PB reports grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Sanofi, personal fees from GSK, outside the submitted work. In addition, PB has 3 patents (i) (EP N°15152886.6 i.e., New compositions and methods of treating and/or preventing Chronic Obstructive Pulmonary Disease), pending; (ii) (EP N°3050574 i.e., Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease), delivered; (iii) (EP N°20173595.8 i.e., New compositions and methods of treating COVID-19 Disease), licensed.
